Thread: (IGXT)Mcap 28 M// Partnership THIS MONTH/1x Approved drug

Results 1 to 5 of 5

  1. #1
    Alinlop
    Guest

    Default

    HIS UNKNOWN GEM IS THE CHEAPEST STOCK WITH THE HIGHEST UPSIDE POTENTIAL IN THE COMPLETE BIOTECH SECTOR .DO YOUR OWN DD AND REALIZE THE MEGA MONSTER POTENTIAL ! GLTA


    This Goldmine has a VERY LOW burn-rate of only $1.2 M a year means we have enuff cash untill 2014 EXCLUDING cpi-300 revenue and EXCLUDING upfront payments from upcoming partnerships BUT MORE IMPORTANT TO KNOW IS THAT WE WILL REACH PROFITABILITY THIS YEAR !!!

    2x NDA filings for Migraine and Antipsychotic drugs this year which have much bigger market potential than current approved drug .

    IGXT has NO DEBT and the Market cap of only 28 M is more than RIDICULOUS for this GOLDMINE .


    Intelgenx (IGXT.OB)

    Market Cap : $ 28 M
    Cash: $ 3.3 M
    Price : 0.60 $
    NO DEBT

    Shares Out : 45 M ( 23 M shares are held by Insiders + Institutions)
  2. #2
    AliseASPIP
    Guest

    Default (IGXT)Mcap 28 M// Partnership THIS MONTH/1x Approved drug

    IntelGenx (IGXT) Submits New Drug Application for Anti-Migraine VersaFilm(TM)

    SAINT LAURENT, Quebec, March 27, 2013 (GLOBE NEWSWIRE) -- IntelGenx Corp. (IGX.V) (IGXT) ("IntelGenx" or the "Company"), a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.
  3. #3

    Default

    The company had previously announced a successful a pre-NDA meeting with the FDA following the successful completion of a bioequivalency study demonstrating that its oral film product is bioequivalent with Maxalt MLT(R), a leading branded anti-migraine product manufactured by Merck & Co. According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012. The thin-film formulation of Rizatriptan has been developed in accordance with the co-development and commercialisation agreement with RedHill Biopharma Ltd. (RDHL) (RDHL) using IntelGenx' proprietary immediate release "VersaFilm(TM)" drug delivery technology.
    IntelGenx' orally disintegrating film consists of a thin (30 -- 50 um) polymeric film which disintegrates rapidly upon oral administration, thereby releasing the active drug Rizatriptan and making it available for rapid absorption. The film does not require water for administration.
  4. #4
    Alina94331
    Guest

    Default

    On announcing the news, IntelGenx' President and CEO Dr. Horst Zerbe commented "We are very excited with this filing as we believe that our Rizatriptan film is the first oral film product for the treatment of migraine for which a 505(b)(2) NDA has been submitted to FDA. We believe that the product has significant market potential as it is therapeutically equivalent to Maxalt-MLT(R) orally disintegrating tablets, is easy to use, and offers significant cost advantages over orally disintegrating tablets due to the fact that manufacturing costs of orally disintegrating tablets are generally higher than those of orally disintegrating films as they often require lyophilization of the drug and a complicated, and therefore very expensive, packaging system."
  5. #5
    Andreyamorn
    Guest

    Default

    About IntelGenx:
    IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, idiopathic pulmonary fibrosis, allergies and pain management.

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts